BRAF inhibitor: targeted therapy in hairy cell leukemia

Slides:

Advertisements

Similar presentations

Hairy Cell Leukemia Foundation and

Advertisements

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.

Extracellular Environment. Extracellular Environment.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Fig. 6. VitabridC12 inhibited cutaneous inflammation via the nuclear factor-κB signaling pathway. Protein extracts were prepared, and western blot analysis.

Advances in Molecular Biology of Lung Disease

Targeting signal transduction

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.

Gene therapy: efficient targeting of hematopoietic stem cells

Uncontrolled Wnt signaling causes leukemia

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

SIGNAL TRANSDUCTION Signal Transduction Pathway Protein Modification Phosphorylation Cascade Protein Kinases.

Inhibitor of MAP kinase activation blocks colon cancer growth

Positioning NK-κB in multiple myeloma

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

How I treat hairy cell leukemia

MAPK pathway inhibitors.

Activation of mitogen-activated protein kinases during preparation of vein grafts and modulation by a synthetic inhibitor Costas Bizekis, MD, Giuseppe.

Rethinking bioactivity of FLT3 inhibitors

V617F “JAKs” up myeloproliferative signal

by Corey S. Cutler, John Koreth, and Jerome Ritz

Figure 4 Possible combination therapies CDK4/6 inhibitors

Targeting kinases in CML CLL

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity by Valentina Pettirossi,

by Walter Zumkeller, and Stefan Burdach

Cell signaling and cancer

Targeted Therapies in Melanoma: Translational Research at Its Finest

On the TRAIL to Overcome BRAF-Inhibitor Resistance

A genome-based strategy uncovers frequent BRAF mutations in melanoma

A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin

Melanoma: New Insights and New Therapies

Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills Cancer Cell

Keiran S.M. Smalley Journal of Investigative Dermatology

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

The RAF Inhibitor Paradox Revisited

The RAS/MAPK Axis Gets Stressed Out

Deletion of the epidermal growth factor receptor in renal proximal tubule epithelial cells delays recovery from acute kidney injury Jianchun Chen, Jian-Kang.

RAS and PD-L1: A Masters’ Liaison in Cancer Immune Evasion

Akihiro Tada Journal of Investigative Dermatology

Conspiracy Theory Cell

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

Kinase signaling and targeted therapy for primary myelofibrosis

Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD

by Christine L. Kempton, and Amanda B. Payne

Platelet-derived growth factor (PDGF) signalling pathway.

Volume 22, Issue 5, Pages (November 2012)

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer Charles M.

The new kid on the block(ade) of the IGF-1 receptor

by Pamela J. Sung, Mayumi Sugita, Holly Koblish, Alexander E

Mutant BRAF Melanomas—Dependence and Resistance

Signaling by Ras/Raf/ERK in the regulation of β-cell proliferation.

ADARs Edit MicroRNAs to Promote Leukemic Stem Cell Activity

CD16 uses additional pathways for killing.

Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study by Jeffrey.

Novel therapies for chronic myelogenous leukemia

by Abigail M. Druck Shudofsky, and Chou-Zen Giam

Attacking Cancer at Its Root

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.

Schematic view of intracellular signaling cascades triggered by receptor tyrosine kinase in Schwann cells. Schematic view of intracellular signaling cascades.

Simplified BRAF signaling network.

Mind the IQGAP Cancer Cell

by Wolfgang Warsch, Christoph Walz, and Veronika Sexl

An overview of the MAPK signaling pathway with points of therapeutic intervention indicated. An overview of the MAPK signaling pathway with points of therapeutic.

Normal pathway of B12 absorption and cellular uptake.

by Jennifer N. Brudno, and James N. Kochenderfer

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor.

Four classes of agents that can be used to treat multiple myeloma.

Therapeutic strategies for different classes of BRAF and MEK mutations

Presentation transcript:

BRAF inhibitor: targeted therapy in hairy cell leukemia by Michael R. Grever Blood Volume 127(23):2784-2785 June 9, 2016 ©2016 by American Society of Hematology

The activated BRAF pathway provides oncogenic signaling to the leukemic hairy cell through the MEK-ERK cascade. The activated BRAF pathway provides oncogenic signaling to the leukemic hairy cell through the MEK-ERK cascade. Vemurafenib is an inhibitor of BRAF in this pathway. The activity of pERK is reduced as a consequence of BRAF inhibition. The reduced pERK results in decreased cell proliferation. This is measured by immunohistochemical analysis and is used as a pharmacodynamics biomarker of BRAF inhibition. P, indicates a phospho-group; RTK, receptor tyrosine kinase. Professional illustration by Patrick Lane, ScEYEnce Studios. Michael R. Grever Blood 2016;127:2784-2785 ©2016 by American Society of Hematology